BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16648986)

  • 1. [Innovation or pseudo-innovation: that is the question].
    Unger T
    Med Klin (Munich); 2006 Mar; 101(3):257-62. PubMed ID: 16648986
    [No Abstract]   [Full Text] [Related]  

  • 2. [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].
    Anlauf M; Hense HW
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1557-9. PubMed ID: 12854069
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hypertension therapy--never without diuretics?].
    Anlauf M
    MMW Fortschr Med; 2007 Nov; 149(46):31-3. PubMed ID: 18069189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Economic or medical innovations: that is the question!].
    Freitag MH; Wohlgemuth WA
    Med Klin (Munich); 2006 Jul; 101(7):590-1; author reply 591-3. PubMed ID: 16897896
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comment on IOWiG report plan. A medical decision may not be replaced].
    Vorstand der Deutschen Hochdruckliga E.V
    MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of hypertension. Cost conscious prevention of complications].
    Kolloch RE
    MMW Fortschr Med; 2003 Nov; 145(47):64. PubMed ID: 14725042
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypertension control: improved, but not enough!
    Alderman MH
    Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338
    [No Abstract]   [Full Text] [Related]  

  • 8. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting.
    Amira CO; Okubadejo NU
    J Hum Hypertens; 2006 Nov; 20(11):894-7. PubMed ID: 16915299
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fully possible to reduce the costs of hypertension treatment].
    Wettermark B; Angman A; Hjemdahl P
    Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treating hypertension only in case of high risk? Evidence-based therapy with cost control].
    Trenkwalder P
    MMW Fortschr Med; 2001 Feb; 143(7):45-6. PubMed ID: 11268751
    [No Abstract]   [Full Text] [Related]  

  • 11. From clinical trials to clinical practice: why the gap?
    Kotchen TA
    Hypertension; 2006 Aug; 48(2):196-7. PubMed ID: 16785333
    [No Abstract]   [Full Text] [Related]  

  • 12. Thiazides first-line treatment for hypertension.
    McCormack J; Rangno R; Wright JM
    Can Fam Physician; 2003 Jul; 49():879. PubMed ID: 12901483
    [No Abstract]   [Full Text] [Related]  

  • 13. [Unfairly implicated as cost drivers. New drugs without a chance?].
    MMW Fortschr Med; 2004 Mar; 146(10):45. PubMed ID: 15347085
    [No Abstract]   [Full Text] [Related]  

  • 14. Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications.
    Robbiano L; Martelli A; Brambilla G
    J Hum Hypertens; 2005 Oct; 19(10):819-22. PubMed ID: 15951739
    [No Abstract]   [Full Text] [Related]  

  • 15. [Rational introduction to new drugs requires both a health care and a community perspective].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergendahl GT; Wiking N
    Lakartidningen; 2009 Jan 7-13; 106(1-2):52. PubMed ID: 19235325
    [No Abstract]   [Full Text] [Related]  

  • 16. [Health care too costly? Saving more than 10 million euros in 2 months!].
    Rappert B
    MMW Fortschr Med; 2003 Nov; 145(47):65. PubMed ID: 14725043
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacoeconomic issues in antihypertensive treatment].
    Saito I
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():271-5. PubMed ID: 16981554
    [No Abstract]   [Full Text] [Related]  

  • 18. [Development of new drugs is too expensive].
    Andreasen J
    Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
    [No Abstract]   [Full Text] [Related]  

  • 19. [Structured introduction of new drug therapies: valuable initiative--transparency required].
    Lundkvist J; Henriksson F
    Lakartidningen; 2009 Jan 7-13; 106(1-2):51. PubMed ID: 19235324
    [No Abstract]   [Full Text] [Related]  

  • 20. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.